Responsibility in Drug Advertising Act of 2025
- Bill Number
- H.R. 1117
- Origin Chamber
- House
- Congress
- 119th Congress, Session 1
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2025-02-07: Referred to the House Committee on Energy and Commerce.
- Last Updated
- 2026-01-21T03:43:39Z
Official Summary
Responsibility in Drug Advertising Act of 2025
This bill prohibits direct-to-consumer advertising of new drugs during the first three years following their approval by the Food and Drug Administration (FDA). Direct-to-consumer advertising includes advertising via social media.
Upon request from a drug’s sponsor, the FDA may waive the prohibition during the third year following a drug’s approval if it determines that the direct-to-consumer advertising of the drug would have an affirmative value to public health. Conversely, the FDA may prohibit such advertising beyond the three-year period following approval if it determines that the drug has significant adverse health effects based on post-approval studies, adverse event reports, and other appropriate resources.
The prohibition applies to new drugs approved beginning one year before the bill’s enactment.
Sponsor
Rep. DeLauro, Rosa L. [D-CT-3]
Recent Actions
- 2025-02-07: Referred to the House Committee on Energy and Commerce.
- 2025-02-07: Introduced in House
- 2025-02-07: Introduced in House
Bill Versions
- Responsibility in Drug Advertising Act of 2025 — issued 2025-02-07 — PDF (4 pages)